Goldman Sachs (India) Alternative Investment Management Private Limited (GS AIMPL) has been hit with a ₹40 lakh penalty by the Competition Commission of India (CCI) for failing to disclose its investment in Biocon Biologics Limited, a requirement under the Competition Act, 2002.
The case revolves around Goldman Sachs’ 2020 acquisition of optionally convertible debentures (OCDs) in Biocon Biologics. If exercised, these debentures would have secured the firm a 3.81% stake in Biocon on a fully diluted basis. However, the transaction, executed under a Securities Subscription Agreement and a Shareholders Agreement (SHA), granted Goldman Sachs rights that went beyond those of a passive investor, including access to board meeting minutes and Biocon’s premises.
After reviewing the deal, the CCI determined that the investment required regulatory notification under Section 6(2) of the Competition Act. A show cause notice was issued to Goldman Sachs after the Commission noted that its involvement in Biocon appeared more strategic than passive.
Goldman Sachs defended its position, arguing that its shareholding remained below 10% and that its investment qualified for exemption under the Combination Regulations. The firm contended that the rights under the SHA did not give it control or material influence over Biocon and that the investment was made in the ordinary course of business. It also pointed out that similar rights were granted to other investors and that confidentiality safeguards were in place to prevent misuse of information.
The CCI rejected these arguments, ruling that the special rights granted to Goldman Sachs—particularly access to board minutes—provided insights into Biocon’s strategic and financial decisions, which could impact competitive dynamics. The Commission further noted that the investment’s extended holding period and Goldman Sachs’ option to convert the debentures into equity indicated a long-term interest rather than a short-term financial transaction.
Stressing that competition laws apply based on the substance of an arrangement rather than its structure, the CCI concluded that Goldman Sachs should have sought approval before proceeding with the investment. As a result, the firm was found liable under Section 43A of the Act and fined ₹40 lakh for non-compliance.